Scientific Technological Pharmaceutical Firm

• Nowadays the Firm ranks among the leaders of pharmaceutical industry in Russia and takes constant care of application of science and state-of-the-art technology achievements to production aiming further improvement of output quality.
• The main principle of STPF “Polysan” is developing original, harmless and high-efficient medicinal preparations.
• The uniqueness of the company consists of organization the whole preparation cycle from the development and registration to the production and sale that available due to the firm’s own scientific laboratory and pharmaceutical production complex.
• STPF “Polysan” has two directions of its activity. First, Polysan is specialized on developing preparations for treating “socially important” diseases that lead to the long disability, invalidity: mass viral infections (hepatitis B, C, flue infections, HIV), bacterial infections and heavy diseases such as acute cerebrovascular accident, ischemia and others. The second direction is developing metabolic preparations on succinic acid basis possessed antioxidantive activity.
• At present the preparations produced by "POLYSAN" are in the list of the most demanded products on pharmaceutical market of Russia. The product range includes prescribed preparations: correctors of the immune status and antioxidants, along with new prospective medicinal preparations.
  The product range includes prescribed preparations: correctors of the immune status and antioxidants, along with new prospective medicinal preparations.

Cycloferon

had become the Firm's brand, firmly established among the preparations of its pharmacological group (immunomodulators interferon inducers). Cycloferon, the antiviral preparation with immunomodulating activity, produced in three medicinal forms: solution for injections, tablets and liniment. Cycloferon is effective in therapy of viral hepatitis, HIV.

Reamberin

is the first preparation of a new generation, the antihypoxic-detoxifying infusion solution on the basis of succinic acid. Reamberin is administered during urgent care in toxicology, in burn injury and surgical pathology, viral hepatitis and enteric infections, severe cases of pneumonia and neuroinfections. These products have been developed and manufactured by the Firm, achieving good sales on domestic market and abroad.
In 2004 the Firm has launched a new preparation on the basis of succinic acid:

Cytoflavin

the preparation for therapy of cerebrovascular accident, encephalopathy and stroke. Administration of this preparation in neurologic intensive care department results in significant reduction in mortality saving lives to tens of thousands of patients.
There are over 10 new original preparations in the portfolio of the Firm that are at different stages of production, development, preclinical and clinical trials. They are designed to be used in urgent surgery, hematology, neurology, cardiology and gerontology.